Tight R R, Bartlett M S
Rev Infect Dis. 1981 Nov-Dec;3(6):1139-50. doi: 10.1093/clinids/3.6.1139.
Actinomycetoma (Madura foot) caused by Actinomadura madurae occurred in an Indiana factory worker. Previous cases of culture-proven actinomycetoma from the United States and reports of drug therapy were reviewed. Treatment with sulfonamides, streptomycin, dapsone, and other antimicrobial agents has been effective. Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy was effective in our case, but sulfadiazine was not. In vitro, SMZ was 16 times more active against the infecting strain of A. madurae than was sulfadiazine, and TMP was inactive, suggesting that our patient's satisfactory treatment might have been due to SMZ alone. Prolonged therapy is usually necessary. Relatively simple immunologic procedures and antimicrobiol susceptibility tests have been useful in the diagnosis and management of actinomycetoma. With appropriate antimicrobial therapy, surgical excision or amputation usually can be avoided. Recommendations for the medical management of actinomycetoma are summarized.
由马杜拉放线菌引起的放线菌性足分支菌病(马杜拉足)发生在一名印第安纳州的工厂工人身上。回顾了美国此前经培养证实的放线菌性足分支菌病病例及药物治疗报告。使用磺胺类药物、链霉素、氨苯砜和其他抗菌药物治疗有效。甲氧苄啶-磺胺甲恶唑(TMP-SMZ)治疗对我们的病例有效,但磺胺嘧啶无效。在体外,磺胺甲恶唑对感染的马杜拉放线菌菌株的活性比磺胺嘧啶高16倍,而甲氧苄啶无活性,这表明我们患者的良好治疗效果可能仅归因于磺胺甲恶唑。通常需要长期治疗。相对简单的免疫程序和抗菌药敏试验对放线菌性足分支菌病的诊断和管理很有用。通过适当的抗菌治疗,通常可以避免手术切除或截肢。总结了放线菌性足分支菌病的药物治疗建议。